Silexion Therapeutics Corp - 8-K Filing

Silexion Therapeutics reports positive preclinical findings for SIL204, demonstrating endogenous systemic uptake in KRAS-driven cancers. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits (d) Exhibits 99)

SEC EDGAR ·

Tickers: $SLXN

Read the full article at SEC EDGAR

More Regulatory news